First Amendment to the Second Amended and Restated By-Laws of Enzon Pharmaceuticals, Inc.
This amendment, approved by the Board of Directors of Enzon Pharmaceuticals, Inc. on February 24, 2022, changes Section 3.2 of the company's by-laws. It sets the number of directors on the Board to a minimum of one and a maximum of fifteen, with the current number set at two unless changed by a majority Board vote. All other by-law provisions remain unchanged.
Exhibit 10.7
FIRST AMENDMENT TO THE
SECOND AMENDED AND RESTATED BY-LAWS
OF
ENZON PHARMACEUTICALS, INC.
On February 24, 2022, the Board of Directors of Enzon Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), unanimously approved and adopted the following amendment to the Corporation’s Second Amended and Restated By-Laws (the “By-Laws”) to be effective immediately:
1. | Section 3.2 of the By-Laws is deleted in its entirety and replaced with the following: |
The Board shall consist of at least one but no more than fifteen directors, the exact number of directors to be determined from time to time by resolution adopted by affirmative vote of a majority of the whole Board and such exact number shall be two until otherwise determined by resolution adopted by affirmative vote of a majority of the whole Board. As used in this Article 3, the term “whole Board” means the total number of directors which the Corporation would have if there were no vacancies.
2. | Except as set forth herein, all other provisions of the By-Laws shall remain in full force and effect. |
